Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)
26.10.2021 13:46:00 EEST | Business Wire | Press release
Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) and Nippon Kayaku Co., Ltd. (TOKYO: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) today jointly announced the conclusion of a license agreement for marketing rights to darinaparsin (generic name, development code: SP-02) in Japan (hereinafter “this agreement”).
Darinaparsin is a drug candidate under development by Solasia for relapsed or refractory peripheral T-cell lymphoma (PTCL). Solasia filed a new drug application with the Ministry of Health, Labour and Welfare in June 2021 and expects to launch after obtaining approval from the agency in 2022.
Mr. Kazuto Koizumi, Managing Director and Head of Pharmaceuticals Group of Nippon Kayaku, commented as follows:
“Solasia is a specialty pharmaceutical company that excels in development of innovative medicines in the field of oncology in Japan and other Asian countries. Through the early launch of darinaparsin developed by Solasia, we expect to provide a new treatment option for PTCL, and contribute to patients and their family suffering from the disease, as well as to healthcare professionals.”
Mr. Yoshihiro Arai, President and CEO of Solasia, commented as follows:
“Nippon Kayaku is one of Japan's leading pharmaceutical companies with strengths in the field of oncology. We are very pleased to have this opportunity to deliver darinaparsin to nationwide medical institutions providing cancer treatment by utilizing Nippon Kayaku’s extensive experience in oncology and strong sales network, and contribute to the treatment of PTCL.”
Based on this agreement, Solasia and Nippon Kayaku will make further efforts to provide a new treatment option to patient suffering from PTCL, for which no standard treatment has been established to date.
###
About Nippon Kayaku
Nippon Kayaku was founded in 1916 as the first industrial explosives manufacturer in Japan. We have developed products to meet the needs of the time by utilizing, combining and transforming our core technologies in the company’s main areas, explosives, dyes, pharmaceuticals and resins. Nippon Kayaku has contributed to realizing a sustainable society through its four businesses of Functional Chemicals, Pharmaceuticals, Safety Systems, and Agrochemicals.
In the Pharmaceuticals Business, Nippon Kayaku specializes in anticancer drugs and other cancer-related products, handling a range of products from new drugs to biosimilars and generics. It strives to provide trustworthy information crucial for understanding anticancer drugs to medical institutions.
Please visit the company website at https://www.nipponkayaku.co.jp/english/ for more information.
About Solasia
Please visit the company website at https://solasia.co.jp/en/ for more information.
About darinaparsin (SP-02)
Please visit at https://solasia.co.jp/en/pipeline/sp02.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005660/en/
Contact information
For further information, please contact:
Nippon Kayaku Co., Ltd.
Public Relations & Investor Relations Division,
Tel. +81 3 6731 5237
Solasia Pharma K.K.
Rie Toyoda, Public Relations and Investor Relations,
Tel. +81 3 5843 8045
info@solasia.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Expands Shopper Experience Platform to Improve Product Discovery in AI-Powered Shopping28.10.2026 13:00:00 EET | Press release
NielsenIQ (NYSE: NIQ)today announced new optimization capabilities for its Shopper Experience Platform, supported by its CONTENT Framework, a seven-pillar approach to evaluating and improving product content. Together, they enable brands to evaluate product content and imagery against retailer requirements and category expectations, identify gaps, and prioritize improvements that strengthen product discovery across retailer sites, search engines, and AI-powered shopping channels. A product can be accurate, complete, and retailer-compliant yet still be difficult for shoppers to find, understand, or choose. This challenge is growing as AI assistants, retailer algorithms, and recommendation engines play a larger role in shopping. According to NIQ's Consumer Outlook: Guide to 2027, 55% of global consumers report having been influenced by AI tools or assistants when making household and grocery purchases, while 65% report being influenced by products recommended or ranked on retailer and sh
Tula Technology Signs Landmark Agreement Licensing Dynamic Motor Drive® to Global Tier 1 Supplier28.10.2026 13:00:00 EET | Press release
Tula Technology, Inc., a leader in propulsion efficiency and developer of Dynamic Motor Drive® (DMD), today announced that it has signed an intellectual property license agreement with a global Tier 1 automotive supplier covering the supplier’s entire E-drive portfolio. Under the agreement, the Tier 1 supplier has a non-exclusive license to Tula’s DMD portfolio of patents covering the U.S., Europe, and Asia. The agreement marks the first commercial deployment of DMD spanning the supplier's complete E‑drive portfolio. DMD is an innovative software‑only technology that strategically applies torque pulses under optimal conditions, reducing drive‑cycle energy consumption by 0.5‑2.0%. Because DMD is implemented entirely in software, it requires no hardware changes or additions, allowing suppliers and OEMs to integrate the technology into existing E‑drive systems with minimal engineering effort. The result is improved efficiency for electrified vehicles, delivering higher fuel economy in hyb
PayNet Enables Malaysian Mobile Banking App Users to Make Overseas DuitNow QR Payments via Alipay+28.10.2026 12:42:00 EET | Press release
Payments Network Malaysia Sdn Bhd (PayNet) today announced the launch of outbound DuitNow QR payment connectivity through Alipay+, the unified wallet gateway of Ant International. Malaysians can now use supported local mobile banking apps to pay at participating Alipay+-supported merchants in five destinations: Chinese Mainland, Hong Kong SAR, South Korea, the Philippines and Laos. The initial three launch banks are Maybank, CIMB and Hong Leong Bank, with Bank Islam set to join soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028063575/en/ From left to right: Michael Guo, General Manager of Alipay+ SEA, ANZ and South Asia, Ant International; Praveen Rajan, Chief Executive Officer of PayNet; Danny Chung, General Manager of Alipay+ Global Growth Center, Ant International; and Azrul Fakhzan B. Mainor, Chief Commercial Officer of PayNet. The launch forms part of PayNet’s long-term roadmap to extend secure and interoperabl
Blue Matter Acquires Cognite, a Leading Healthcare Communications Agency28.10.2026 12:00:00 EET | Press release
Blue Matter, a world-class consulting firm serving the life sciences industry, today announced the acquisition of Cognite, a leading global healthcare communications agency that helps pharmaceutical and biotech companies bring science to life through an impressive range of scientific, medical, and commercial communications services. Cognite represents a significant step forward in strengthening Blue Matter’s growing range of communications capabilities. “Blue Matter is recognized as a valuable strategic resource and a thought leader when it comes to corporate, portfolio, product, and functional strategy in biopharma,” said Blue Matter CEO Ashwin Dandekar. “Over the past few years, we’ve been systematically bringing together the creative and communications capabilities that are often so crucial to bringing those strategies to life with healthcare providers, patients, payers, investors, and other stakeholders. Cognite’s array of capabilities, creativity, and team culture are a perfect fi
euroAtlantic Airways Adds Second A330-300, Expanding Widebody Capacity28.10.2026 12:00:00 EET | Press release
euroAtlantic Airways (“EAA”), a Njord Partners portfolio company and a Portuguese ACMI and charter airline, has added a second Airbus A330-300 leased from Jackson Square Aviation (JSA), further expanding its widebody capacity. The second aircraft arrived in Portugal on 28 October 2026, bringing EAA’s total fleet size to eight. The first aircraft, CS-TGI, has already been inducted into EAA’s Air Operator Certificate and is operating commercial flights, including short-term ACMI and charter assignments. The second aircraft, an Airbus A330-300 which will carry the registration CS-TGJ, will now go through induction into EAA’s Air Operator Certificate, subject to the usual regulatory approvals. Both aircraft are leased from JSA and seat 290 passengers across three classes. The addition of the second aircraft strengthens EAA’s ability to serve a diversified range of customer requirements across global markets. In line with its long-term plans, EAA is well positioned for continued disciplined
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom